Evommune (EVMN) Return on Capital Employed (2025 - 2026)
Evommune's (EVMN) quarterly Return on Capital Employed came in at 31.18% in Q1 2026, up 46.36% on a QoQ basis from 58.12% in Q4 2025.
Evommune (EVMN) Return on Capital Employed (2025 - 2026) Analysis & Trends
Evommune (EVMN) has 2 years of Return on Capital Employed data on file, last reported at 31.18% in Q1 2026.
- On a quarterly basis, Return on Capital Employed changed N/A year-over-year to 31.18% in Q1 2026; TTM through Mar 2026 was 31.18%, a N/A change from a year earlier, with the FY2025 full-year figure at 61.14%, changed N/A from the prior year.
- Return on Capital Employed for Q1 2026 stood at 31.18%, up from 58.12% in the prior quarter.
- Over the last five years, Return on Capital Employed for EVMN reached as high as 31.18% in Q1 2026 and fell as low as 58.12% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Evommune | 381.48 Mn | 170.02 Mn | - | -31.18% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -31.18% |
| Dec 31, 2025 | -58.12% |